Results 31 to 40 of about 14,813,386 (261)

The CAR T‐Cell Mechanoimmunology at a Glance [PDF]

Advanced Science, 2020
Abstract Chimeric antigen receptor (CAR) T‐cell transfer is a novel paradigm of adoptive T‐cell immunotherapy. When coming into contact with a target cancer cell, CAR T‐cell forms a nonclassical immunological synapse with the cancer cell and dynamically orchestrates multiple critical forces to commit cytotoxic immune function. Such an
Rui Li, Chao Ma, Haogang Cai, Weiqiang Chen   +3 more
openaire   +2 more sources

Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities [PDF]

, 2023
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can hamper the clinical benefit of CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL).
Dutch CAR-T Tumorboard Consortium
core  

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-Cell Stemness Shows Enhanced CAR T-Cell Efficacy in Preclinical and Early Clinical Development.

, 2023
CAR T-cell product quality and stemness (Tstem) are major determinants of in vivo expansion, efficacy, and clinical response. Prolonged ex vivo culturing is known to deplete Tstem, affecting clinical outcome.
Davis, Jaclyn, Engels, Boris, Quinn, David, Shah, Nirav N., Treanor, Louise, Price, Andrew, Sohoni, Akash Kamalakar, Mataraza, Jennifer, Briones, Javier, Shune, Leyla, Zhu, Xu, Moschetta, Michele, Bondanza, Attilio, Marchal, Anne-Laure, Yang, Jennifer, Barba, Pere, Orlando, Elena, Blaise, Didier, Lu, Darlene, Mariconti, Luisa, Xu, Zhu, Flinn, Ian, Brogdon, Jennifer, Boissel, Nicolas, de Parseval, Laure, Jäger, Ulrich, Dickinson, Michael   +26 more
core   +1 more source

The CAR T Cell Story

healthbook TIMES. Oncology Hematology, 2019
During the entire 20^th^ century, chemotherapy and irradiation were the mainstay of non-surgical cancer treatment. In the past 20 years, however, cancer immunotherapy has been revolutionizing the field of oncology with ever-increasing pace.
Norman Russkamp, Thorsten Zenz
doaj   +1 more source

A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization

Frontiers in Immunology, 2021
Chimeric antigen receptor (CAR) T cell performance against solid tumors in mouse models and clinical trials is often less effective than predicted by CAR construct selection in two-dimensional (2D) cocultures.
Laura Grunewald, Laura Grunewald, Tobias Lam, Tobias Lam, Lena Andersch, Anika Klaus, Silke Schwiebert, Annika Winkler, Anton Gauert, Anja I. Heeren-Hagemann, Kathy Astrahantseff, Filippos Klironomos, Alexander Thomas, Alexander Thomas, Hedwig E. Deubzer, Hedwig E. Deubzer, Hedwig E. Deubzer, Hedwig E. Deubzer, Anton G. Henssen, Anton G. Henssen, Angelika Eggert, Angelika Eggert, Angelika Eggert, Angelika Eggert, Johannes H. Schulte, Johannes H. Schulte, Johannes H. Schulte, Kathleen Anders, Kathleen Anders, Lutz Kloke, Lutz Kloke, Annette Künkele, Annette Künkele, Annette Künkele, Annette Künkele   +34 more
doaj   +1 more source

CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma

BMC Medicine, 2023
Background Natural killer/T cell lymphoma (NKTCL) is an aggressive lymphoma with a poor prognosis. Chimeric antigen receptor-transduced T (CAR-T) cell therapy has become a promising immunotherapeutic strategy against haematologic malignancies. Methods In
Hongwen Li, Wenting Song, Jiazhuo Wu, Zhuangzhuang Shi, Yuyang Gao, Jiwei Li, Lijuan Han, Jianxiang Zhang, Zhaoming Li, Yong Li, Mingzhi Zhang   +10 more
doaj   +1 more source

Mechanisms of CAR T cell exhaustion and current counteraction strategies

Frontiers in Cell and Developmental Biology, 2022
The functional state of chimeric antigen receptor T (CAR T) cells determines their efficacy in vivo. Exhausted CAR T cells exhibit decreased proliferative capacity, impaired anti-tumor activity, and attenuated persistence.
Xiaoying Zhu, Qing Li, Xiaojian Zhu
doaj   +1 more source

Antigenic cells augment CAR T cells [PDF]

Blood, 2020
Publisher's Note: The Blood article that is discussed in this commentary has been retracted. The authors of this commentary were not involved with the original article's retraction.
openaire   +2 more sources

CAR T Cell Locomotion in Solid Tumor Microenvironment

, 2022
The promising outcomes of chimeric antigen receptor (CAR) T cell therapy in hematologic malignancies potentiates its capability in the fight against many cancers.
Haipeng Tao, Sawyer, William W., Duy T. Nguyen, Hector R. Mendez-Gomez, Wang, Theodore, Matthew Cascio, Liu, Ruixuan, Rubin, Jacob, Jin, Linchun, Nguyen, Duy T., Cascio, Matthew, Castillo, Paul, Elias J. Sayour, Mitchell, Duane A., Elizabeth Ogando-Rivas, W. Gregory Sawyer, Tao, Haipeng, Sawyer, W. Gregory, Theodore Wang, Jacob Rubin, Ogando-Rivas, Elizabeth, Ruixuan Liu, Jianping Huang, Duane A. Mitchell, Paul Castillo, Huang, Jianping, Linchun Jin, William W. Sawyer, Sayour, Elias J., Mendez-Gomez, Hector R.   +29 more
core   +1 more source

Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality

OncoImmunology, 2022
Successful translation of chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors has proved to be troublesome, mainly due to the complex tumor microenvironment promoting T cell dysfunction and antigen heterogeneity.
Esther Schoutrop, Stefanie Renken, Isabella Micallef Nilsson, Paula Hahn, Thomas Poiret, Rolf Kiessling, Stina L Wickström, Jonas Mattsson, Isabelle Magalhaes   +8 more
doaj   +1 more source